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Pre-exposure prophylaxis (PrEP) has demonstrated remarkable effectiveness protecting at-risk individuals from 
HIV-1 infection. Despite this record of effectiveness, concerns persist about the diminished protective effect 
observed in women compared with men and the influence of adherence and risk behaviors on effectiveness in 
targeted subpopulations. Furthermore, the high prophylactic efficacy of the first PrEP agent, tenofovir disoproxil 
fumarate/emtricitabine (TDF/FTC), presents challenges for demonstrating the efficacy of new candidates. Trials 
of new agents would typically require use of non-inferiority (NI) designs in which acceptable efficacy for an 
experimental agent is determined using pre-defined margins based on the efficacy of the proven active comparator 
(i.e. TDF/FTC) in placebo-controlled trials. Setting NI margins is a critical step in designing registrational studies. 
Under- or over-estimation of the margin can call into question the utility of the study in the registration package. 
The dependence on previous placebo-controlled trials introduces the same issues as external/historical controls. 
These issues will need to be addressed using trial design features such as re-estimated NI margins, enrichment 
strategies, run-in periods, crossover between study arms, and adaptive re-estimation of sample sizes. These 
measures and other innovations can help to ensure that new PrEP agents are made available to the public 
using stringent standards of evidence.
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Introduction
Pre-exposure prophylaxis (PrEP) against HIV-1 acqui-
sition provides a defense in the fight against the HIV 
global pandemic. Numerous trials have shown the effi-
cacy of PrEP in providing protection, but substantial 
work remains to promote access and adherence, under-
stand potential safety issues (particularly long-term side 
effects), and develop a broader array of PrEP products to 
meet the diverse needs of people at high risk of HIV-1 
infection. Having a broad array of PrEP products, either as 
new modalities, new technologies, or new agents, would 
provide important options to individuals seeking protec-
tion from HIV-1 infection. In this article, we summarize 
the current state of knowledge regarding late-stage PrEP 
study design, discuss specific issues encountered in prior 
studies, and suggest innovations for smaller trials that 
retain a level of sensitivity sufficient to detect meaningful 
effects of preventive interventions.
A substantial and growing body of evidence sup-
ports the use of daily, oral tenofovir disoproxil fuma-
rate/emtricitabine (TDF/FTC) to protect against HIV-1. 
Oral TDF/FTC was approved for use as PrEP by the US 
Food and Drug Administration (FDA) in 2012,1,2 South 
Africa’s Medicines Control Council in 2015,3 and the 
European Medicines Agency in 2016.4 The World Health 
Organization (WHO) recently revised its antiretroviral 
guidelines to recommend oral PrEP containing TDF as 
a prevention option to all people at substantial risk of 
acquiring HIV-1,5 suggesting that TDF/FTC will become 
a critical component of the HIV-1 prevention effort.
The efficacy of TDF/FTC is remarkable, with high pro-
tection demonstrated in highly adherent populations.6–10 Correspondence to: Amy Cutrell, ViiV Healthcare, 5 Moore Dr, Research Triangle Park, NC 27709, USA. Email: amy.g.cutrell@viivhealthcare.com
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Various lines of evidence support a high degree of protec-
tion if the concentration of active drug is sufficiently high 
when an individual is exposed to HIV-1, especially among 
men who have sex with men (MSM).6–9 In the IPrEx trial, 
the relative risk (RR) of HIV-1 acquisition was reduced by 
an estimated 92% (95% confidence interval [CI], 40–99; 
p < 0.001) among participants with detectable levels of 
TDF/FTC compared with participants without detectable 
levels.6 The regimen resulted in an 86% reduction in HIV-1 
acquisition when taken on demand in the IPERGAY study 
(n = 445)8 and when taken daily in the PROUD study 
(n = 544).7 Both incidents of post-enrollment HIV-1 infec-
tion in the arm of the PROUD study that received TDF/
FTC immediately (n = 275) occurred in individuals who 
seemed to have suboptimal adherence.7 Additionally, no 
HIV-1 diagnoses were reported during 388 person-years 
of follow-up (upper limit of 1-sided 97.5% CI, 1.0) in a 
cohort study in San Francisco, California.9
Despite the positive results in these studies in MSM, 
concerns have been raised about the effectiveness of PrEP 
in women. Some women-only studies failed to demon-
strate significantly reduced risk of HIV-1 infection11,12 
in contrast to positive findings in trials that enrolled 
both men and women.10,13,14 While there may be biolog-
ical explanations for this disparity, including the lower 
concentrations of TDF and FTC metabolites that have 
been detected in vaginal mucosa compared with rectal 
mucosa,15 there is a strong correlation between adherence 
and observed efficacy16 (Figure 1). The two major tri-
als that failed to show effectiveness of daily TDF/FTC 
in women (VOICE and FEM-PrEP)11,12 also identified 
low levels of adherence (21–30%). However, in trials in 
which women were more adherent to a daily regimen, 
a significantly reduced risk of HIV-1 acquisition was 
demonstrated.10,13 In the Partners PrEP study, which used 
daily tenofovir, risk of HIV-1 acquisition in women was 
reduced by 71% versus placebo (p = 0.002),10 and in the 
TDF2 Study Group trial, the protective efficacy of TDF 
in the as - treated cohort of women was 75% versus pla-
cebo (p = 0.02).13 In the most recent prevention studies 
in women, a monthly vaginal ring containing dapivir-
ine (DPV) reduced the risk of HIV-1 infection among 
African women (27% lower than placebo in ASPIRE and 
31% lower in the Ring Study), particularly in subgroups 
with evidence of increased adherence.17,18 When viewed 
together, the PrEP trial results show a strong association 
between trial-level adherence and efficacy for both men 
and women. While it may not account for all the varia-
bility, addressing these disparities in adherence and effi-
cacy in PrEP trials for different risk populations remains 
a challenge for the design of future HIV-1 prevention 
research. The trial design features discussed in this article 
offer innovations that can help to ensure that new PrEP 
agents available to the public adhere to stringent stand-
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Figure 1 Relative risk reduction values from the major PrEP trials for men and women according to adherence (measured by 
plasma level of TDF). The solid line represents the meta-regression fit for all groups combined, and the dashed lines represent 
the 95% confidence intervals for the regression line. Plot circle size is proportional to the number of events observed in each 
study. Hollow points show studies (or arms) comparing TDF to placebo, filled points depict TDF/FTC studies. FTC, emtricitabine; 




























 HIV Clinical Trials  2017 3
Cutrell et al. Era of effective pre-exposure prophylaxis
General issues for design
Until validated surrogate endpoint(s) for HIV-1 infection 
or markers of product activity are identified, late-stage 
clinical trials will continue to use HIV-1 seroconversion 
as the primary endpoint.19 Given its proven effective-
ness and approvals, TDF/FTC is likely to be used as an 
active control in clinical trials evaluating new agents for 
PrEP. In an active-controlled study, the trial hypothesis 
may be a non-inferiority (NI) test, a superiority test, or 
nested hypotheses, first evaluating NI and then superiority. 
Superiority studies are appropriate when there is a real-
istic expectation that the experimental agent will reduce 
the infection rate below that seen with the active-con-
trol agent. Non-inferiority studies are possible once an 
active control is proven effective and when it could be 
ethically acceptable to sacrifice some small degree of 
the efficacy associated with the active control. Despite 
their complications,20,21 NI designs are likely to be cho-
sen for new PrEP agent studies after careful considera-
tion of three main issues. First, it may not be realistic to 
expect a new product to reduce the infection rate below 
that seen with TDF/FTC given its high effectiveness in 
adherent populations. Second, a new product that offers 
advantages in either adherence (e.g. long-acting injecta-
ble or implantable PrEP) or safety profile would likely 
be considered acceptable even if it were slightly less 
effective than oral TDF/FTC. Finally, use of a placebo 
control may be considered unethical when TDF/FTC (or 
another agent) has been established to be effective in a 
risk population. Although future trials will undoubtedly 
include NI designs, the feasibility challenges of current 
approaches make it important to consider alternatives that 
offer innovative solutions.
Non-inferiority margins
The NI margin is the degree to which the experimen-
tal intervention can have lower efficacy than the active 
control without being considered clinically unacceptably 
worse. At minimum, the NI margin must be set to retain 
some superiority over no pharmaceutical intervention 
(NPI) to ensure superiority over a hypothetical placebo 
arm. The term “NPI” reflects the fact that the assignment 
is not strictly to placebo but also includes the counseling 
package for prevention. To make a comparison with an 
active control, NI trials make an assumption of constancy 
under which the benefit of an active agent over placebo 
seen in previous studies applies in the new trial setting. 
Defining the NI margin requires knowledge of the benefit 
provided by the active control, preferably based on mul-
tiple high-quality controlled trials of the active control 
versus placebo. The lower bound of that known efficacy 
is referred to as the M1 margin by FDA guidelines and is 
estimated based on the lower limit of the 95% CI from 
a meta-analysis of existing placebo-controlled trials.20–22 
This approach provides a conservative estimate of effi-
cacy, acknowledging the uncertainties of sampling varia-
tion and the potential that the constancy assumption may 
not be perfectly satisfied in a new study.
Establishing the NI margin requires an assumption 
about the “clinically acceptable” degree of inferiority21 
or the proportion of the active comparator drug effect 
that must be preserved. This is the M2 margin, which 
is always stricter than M1.
23 The M2 margin is typically 
set to preserve a fixed proportion of M1 because it is 
believed to be clinically and ethically important that 
a new prevention modality not just provide minimal 
efficacy but also preserve a meaningful amount of the 
active-control effect. One common approach is to set 
the M2 margin to preserve 50% of the benefit ensured 
by the M1 margin. In a successful trial, the upper 95% 
confidence bound on the relative efficacy rate (experi-
mental treatment vs active control) will fall below the 
pre-specified M2 margin.
To begin to determine the NI margin for the likely 
comparator for many future studies of PrEP, we conducted 
a meta-regression of data from FEM-PrEP,12 VOICE,11 
iPrEX,6 Bangkok,14 Partners PrEP,10 TDF2 (Botswana),13 
and IPERGAY.8 The PROUD study results7 were not 
included in the model due to lack of a parallel adherence 
measure. Adherence was assessed by measuring plasma 
concentrations of tenofovir; however, the threshold for 
defining adherence was not the same in all trials. Threshold 
values ranged from 0.1 to 10 ng/mL, but most trials used a 
threshold of 0.31 ng/mL. Results demonstrated a clear and 
consistent association between trial-level adherence and 
TDF/FTC efficacy (Figure 1). The meta-analysis allows 
Table 1 Meta-regression of data from FEM-PrEP,12 VOICE,11 iPrEX,6 Bangkok,14 Partners PrEP,10 TDF2 (Botswana),13 and IPER-
GAY8: Sex-specific margins based on combined model
Note: NI, non-inferiority; RR, relative risk for HIV seroconversion.
aActivity of active control and experimental agent are assumed to be equal.
Men Women
Adherence, % 45 65 85 45 65 85
RR estimate 0.69 0.43 0.28 0.76 0.48 0.31
RR upper bound 0.98 0.59 0.4 0.96 0.67 0.49
Implied NI margin, M2 1.01 1.3 1.59 1.02 1.22 1.42
Events required to 
demonstrate NIa
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experimental agent compared with control decreases 
as adherence rises and, consequently, the sample size 
required to show superiority increases.
Blinding
Whether PrEP trials should be blinded or unblinded was 
heavily debated in the microbicide field. Arguments for 
having an unblinded condom-only or no-gel arm in addi-
tion to a gel-placebo arm were made by Fleming and 
Richardson24 in 2004 and debated in subsequent corre-
spondence.25–29 The main argument at that time in favor 
of an unblinded control group was doubt as to whether 
the placebo was truly inert or did provide some protection 
against HIV-1 infection through, for example, increased 
lubrication or dilution of semen.28 It was also argued that 
having a condom-only control group permits measure-
ment of real-world effectiveness and accounts for behav-
ior change, which may be associated with knowledge of 
PrEP use.25
These debates were partially informed by the HPTN035 
study that included both a gel-placebo and a condom-only 
control arm30 and demonstrated no difference between the 
two control arms in HIV-1 risk behavior, pregnancy rates, 
or HIV-1 or other sexually transmitted infection rates. 
This suggested that sexual behavior was not affected by 
lack of blinding, but it provided no insight on whether 
adherence was affected. For trials that measure efficacy 
without a need to evaluate patient preference, it may be 
preferable to include a blinded comparison group, par-
ticularly when the routes of administration are similar.
However, debates continue as to whether treatment 
blinding is necessary or not when administration routes 
substantially differ (e.g. injectable vs oral treatment). An 
open-label design would enable the evaluation of patient 
preference for the different modes of drug delivery, with 
adherence not being impacted by the double-dummy 
requirements for a blinded comparison. In addition, the 
conduct of the study would not be encumbered by the 
complexity of administering double-dummy products 
(e.g. sham injections). Guarding against the introduction 
of bias would be an important consideration, although 
that would be somewhat mitigated because the endpoint 
of seroconversion is objective rather than subjective.
Base-case non-inferiority design and sample 
size
The meta-analysis of historical studies previously 
described yields estimates of the efficacy of TDF/FTC 
over placebo for a given level of adherence. Table 3 out-
lines considerations for trial designs in different popu-
lations. TDF/FTC will likely be included as the active 
control in future PrEP trials among MSM populations. 
For this analysis, we assumed that adherence to TDF/
the estimation of the observed (RR estimate) and demon-
strated (RR upper bound) effect of TDF/FTC, conditional 
on sex and a given level of adherence.
Table 1 provides estimates of the demonstrated 
effect for men and women assuming 45, 65, and 85% 
adherence rates, as well as potential NI margins. For 
adherence of 45%, TDF/FTC exhibits a modest but 
significant improvement compared with NPI (demon-
strated effects of 0.98 and 0.96 in men and women, 
respectively). As adherence increases so does the 
demonstrated effect of TDF/FTC. Table 1 also shows 
the consequent M2 margins derived from these esti-
mated effects. With the lowest levels of adherence and 
similarity among treatment efficacies, the impractical-
ity of conducting an NI study is obvious because it 
could require more than 100,000 HIV infections. Yet, 
as the estimated effect of TDF increases, the NI margin 
becomes wider (from 1.02 to 1.42 for women). Similar 
estimates could be generated for any trial based on the 
projected population and level of adherence.
Sample size
PrEP trials have traditionally assessed the relative 
reduction of HIV-1 infection between arms during the 
trial period by monitoring the occurrence and timing 
of HIV-1 infections. For these trials, in addition to 
alpha (the probability of a type 1 error) and power, 
sample size depends on two factors: the signal (i.e. 
treatment difference) that the trial must detect and the 
incidence rate in the population to be studied.20 The for-
mer determines the number of events required and the 
latter determines how many person-years are required 
to observe those events. In a superiority study, the treat-
ment difference is the expected reduction, or perhaps 
clinically meaningful reduction, in the infection rate in 
the experimental arm compared with the control arm. 
In an NI study, the treatment difference is the potential 
acceptable loss of efficacy or M2.
20 Represented by the 
hazard ratio (HR), the H0 for a superiority test would 
typically be that HR ≥ 1 (no difference or worse) and 
for an NI test that HR ≥ M2 (difference as bad as or 
worse than M2). The H1 for a superiority test would 
be that HR is, for example, 0.8 (experimental is 20% 
better than control) and for an NI test that HR < 1 (no 
difference or better than control). Table 2 shows sample 
size considerations for NI and superiority hypotheses 
under various assumptions for men and women using 
results from the meta-regression described in Table 1. 
For NI hypotheses, the demonstrated effect of TDF/
FTC and the width of the NI margin correlate directly 
with adherence. Thus, the number of events required to 
demonstrate NI decreases as adherence increases. For 
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that adherence rates in women might improve. It is there-
fore worth considering innovations that could reduce sam-
ple sizes or lead to more reliable inferences about the 
relative benefits of treatment options.
Potential design innovations
Combined non-inferiority/superiority designs
Concerns over sample size can sometimes be managed by 
combining NI and superiority endpoints in a trial design 
with an active control. In a superiority study among MSM 
with an assumed 65% adherence rate to TDF/FTC, H0 is 
no difference and H1 is a relative difference of at least 
54% (HR = 0.46). In this setting, the signal is a difference 
of 54% (Table 2). If a degree of clinical inferiority, such 
as HR = 1.3, is acceptable, then H0 is HR = 1.3 and H1 is 
HR = 0.46, making the signal a relative difference of 65% 
and requiring 40 events instead of 611. Similarly, a stand-
ard NI study among women using DPV rings as a compar-
ator requires more than 100,000 events. An agent with a 
reasonable expectation of 74% efficacy over DPV could 
be studied in an NI/superiority design with 23 events.
Such a bare-minimum sample size has risks. The first 
example has 90% power to show NI (to beat a worst-case 
scenario of HR = 1.3) but not to show superiority (beating 
a no-difference scenario of HR = 1). If the true bene-
fit of the investigational intervention does not match its 
assumed value (or adherence to TDF/FTC is greater than 
expected), there may not even be 90% power to show NI. 
The target populations for superiority and NI trials differ, 
whereas NI studies require conditions of moderate-to-high 
adherence to justify the constancy assumption.
Pre-specified re-estimation of non-inferiority 
margins
Adherence is not reliably predictable, especially with 
participant-controlled dosing. The iPrEX study found 
moderate adherence, moderate efficacy (50% reduction 
in infection rates), and a 2–3% per annum rate of infection 
for patients on TDF/FTC.6 The IPERGAY and PROUD 
studies demonstrated greater adherence, greater efficacy 
(~85% reduction in infection rates), and a lower infec-
tion rate.7,8 If adherence to the active control in the new 
trial is lower than in previous trials, its effect (relative to 
placebo) in the new trial will be lower than expected and 
the pre-defined NI margin too generous. This could lead 
to acceptance of an experimental drug that does not pro-
vide benefit. Alternatively, adherence rates may be higher 
than in prior trials, making the pre-specified M2 margin 
too stringent, leading to the inappropriate rejection of a 
new agent.
By using an objective laboratory measure of drug 
adherence, together with a model for the relationship 
FTC would be 65%, leading to an NI margin of 1.3 among 
MSM (per Table 2).
The anticipated reduction in infection rate is dependent 
on the investigational agent. For studies of oral agents 
or new dosing regimens for TDF/FTC in men, there is 
little reason to expect an improvement in efficacy. These 
studies are therefore classic NI designs with 611 events 
potentially required.
Long-acting formulations or vaccines may address 
the adherence challenges for daily oral PrEP. Such an 
experimental intervention could overcome the chal-
lenge of uncertain adherence in other settings, because 
exposure would be directly observed in these cases and, 
thus, known. If such an intervention were expected to 
be 80% effective compared with NPI, making the inci-
dence on this intervention roughly one-half that seen 
on TDF/FTC, 72 events would be required to test a 
superiority hypothesis.
The anticipated reduction in infection rate is also 
dependent on some amount of nonadherence to TDF/FTC. 
If adherence to TDF/FTC is 85% (instead of 65%) and 
its efficacy relative to NPI is 72%, the effectiveness of a 
vaccine/long-acting agent with 80% efficacy relative to 
NPI is only slightly superior to that of TDF/FTC (Table 2). 
Thus, a larger sample size would be required for adequate 
power to demonstrate superiority (n = 372 events).
Current WHO guidelines recommend offering oral 
PrEP containing TDF as part of the prevention package 
to all people at substantial risk of HIV infection.5 This 
implies that the control arm in prevention trials among 
women will likely provide participants with TDF, rais-
ing the possibility of employing an NI design. Without 
improved adherence, however, it is not possible to 
define an NI margin for the use of TDF/FTC in women 
because it has not reliably demonstrated improvement 
over placebo.
It is possible to define a margin for DPV rings as a 
comparator, albeit one that is so narrow (NI margin, 1.02 
at 45% adherence) that an NI study would require a pro-
hibitive number of events (n = 110,028). The base-case 
sample size is only feasible for agents with a reasonable 
possibility of superiority to the comparator. We assumed 
an adherence rate of 45%, the upper end of that seen in 
studies of women (excepting serodiscordant couples). 
With assumed effectiveness of an experimental agent over 
a control of 71%, a superiority study in this setting would 
require 24 events. In contrast, some of the sample sizes 
described in Table 2 are prohibitive. The power of a study 
is often dependent on the rate of adherence to the active 
control in the trial, yet this cannot be predicted reliably 
when a study is being planned. Given the relationship 
between adherence and efficacy, and the growing body of 
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Run-in designs
A run-in period is the time before randomization in a clin-
ical trial during which no treatment is given but specific 
characteristics are evaluated (e.g. adherence to an inac-
tive but measurable compound). Data from this stage of 
the trial are used as a baseline stratification factor or to 
 characterize noncompliant participants. The run-in period 
is an example of an enrichment strategy and can be used 
to encourage adherence by making participants aware of 
the conditions and demands of the trial.23
The duration of the run-in period should be carefully 
considered. A short run-in period may not provide real-
istic estimates of the adherence rates expected during a 
long study. A long run-in period increases the cost of the 
study without providing data addressing the primary and 
secondary objectives.
At the end of the run-in period, an assessment of 
adherence could be used to identify levels for a stratified 
randomization or to cap the number of participants with 
low adherence (for an NI study) or with  high-adherence 
(for a superiority study) levels. If adopted, the run-in 
period will increase the overall study duration and the 
number of individuals required at screening to enroll 
participants who meet enrichment criteria. Therefore, 
this approach may not lead consistently to cost reduc-
tions, and it can be expected to produce benefits for the 
trial only if adherence can be measured reliably at the 
end of the run-in period.
Crossover designs
In the crossover family of designs, trial participants are 
randomly assigned to a new agent or a control drug, 
assessed for a defined period of time, and then switched 
to the opposite treatment arm and reassessed.32 Although 
they were once thought to be inappropriate for absorb-
ing endpoints such as HIV-1 infection, crossover designs 
have been shown to be statistically valid and efficient 
under certain circumstances.32–34 For a superiority study, 
a crossover design has the same efficiency as a parallel 
design in the absence of heterogeneity. The crossover 
design gains potentially substantial efficiency as heter-
ogeneity increases. An advantage of crossover designs 
is that they do not require measurement of heterogeneity 
(both in infection risk and treatment adherence) to control 
for it. However, if heterogeneity can be measured and con-
trolled by an approach such as stratification, the advantage 
of the crossover design may be diminished. There are 
operational challenges to a crossover design, including 
the time needed to observe trial participants for two time 
periods rather than one, the issue of seroconversion in 
period one, the potential for carryover effects, and a prob-
able increase in discontinuation rates. This innovation is 
not appropriate for vaccines or agents with long half-lives 
between drug concentrations and reduced HIV-1 inci-
dence, it may be possible to pre-specify adjusting the NI 
margin16 to a margin that corresponds to the observed 
active-control arm adherence in the trial. For instance, 
the adherence/efficacy association can be quantified using 
meta-analysis (Figure 1) and adherence measured in the 
active-control arm in the new trial (using the same plas-
ma-level concentration of the control arm study drug). 
These adherence measures can be used to estimate the 
effect of the active control compared with a hypothetical 
placebo arm (M1). The NI margin used to assess the new 
therapy can then be re-computed based on the estimated 
M1 margin, including corrections that preserve an appro-
priate pre-specified level of benefit relative to placebo.
There is tension between the need to state an a priori 
standard for establishing NI and the desire to choose a 
margin that will correctly characterize the efficacy of the 
active control in the NI trial. Careful study of the statistical 
and operational implications of re-estimating the margin 
is needed. The precise formula and algorithm to be used 
for margin re-estimation would need to be pre-specified 
in the protocol.
Enrichment approaches to trial enrollment
Enrichment refers to preferential enrollment of certain 
participants in a study. A biomarker present at randomiza-
tion can be used to determine whether individuals belong 
to a subgroup with characteristics that might offer spe-
cific advantages to trial outcomes. Adaptive enrichment 
is a variation in which interim analyses are conducted 
on observed efficacy in subgroups to determine which 
types of individuals to continue enrolling, with eligibility 
criteria updated adaptively. These designs preserve type 1 
error and may provide an increase in power.
Selection of study participants and settings is impor-
tant and guided by current ethics guidelines. The like-
lihood of seeing an effect of a preventive product is 
increased by enrolling a population at higher risk of 
HIV-1 infection (prognostic enrichment). Another type of 
enrichment would be to choose those likely to respond to 
the preventive drug, or those likely to use the experimen-
tal agent while less likely to adhere to the active-control 
agent (predictive enrichment).31 Successful outcomes are 
favored by low heterogeneity of a population, decreasing 
nondrug-related variability primarily by improving rates 
of adherence. If we could rely on participant character-
istics observed in previous trials that correlate with high 
rates of adherence to the experimental intervention or 
high risk of HIV-1 infection, we could use pre-randomi-
zation characteristics of the current trial to continue pref-
erentially enrolling subjects who are likely to be highly 
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observation could be explained by two possible scenarios. 
In Scenario 1, the new trial may have been conducted in a 
population with a low underlying risk of HIV-1 infection 
with various levels of adherence to PrEP, and the trial 
simply has insufficient data to establish effectiveness. In 
Scenario 2, the trial may have been conducted in a popu-
lation with a high underlying risk of HIV-1 infection with 
high levels of adherence in both study arms. The efficacy 
of a new intervention as a PrEP agent relative to the stand-
ard of care can only be demonstrated in Scenario 2. To 
separate these explanations, the key issue is establishing 
the underlying HIV-1 infection risk without pharmaceu-
tical intervention in the study population. Knowing the 
outcomes of placebo would provide a useful context for 
interpreting a treatment effect. However, a rigorous esti-
mate of the placebo effect is difficult in practical terms. 
An idealized trial design would incorporate a contempo-
raneous control group, such as a randomized no-treatment 
arm, but this is ethically unacceptable in many contexts. 
Hence, the NPI risk of a trial population must be estimated 
by other means.
There are certain populations (e.g. perinatal transmis-
sion, serodiscordant couples) for whom the risk of HIV 
transmission is from a known source and thus ongoing 
and well characterized. Predictions based on the observed 
rates of infection in one population can be adjusted to 
account for different distributions of baseline character-
istics.36 A compelling reduction from a projected risk to 
an observed risk can add indirect evidence to the case for 
Scenario 2 rather than Scenario 1 previously discussed.
Using external historical controls (including partici-
pants from the preparedness phase when a clinical trial is 
planned) is an inferior option because of the concern that 
HIV-1 infection rates may be based on a group who no 
longer resembles the trial population. However, in light 
of the ethical considerations and current WHO guidelines, 
as well as the challenges of planning and conducting 
extremely large complicated NI trials, if it is clear that 
the risk of HIV-1 exposure remains consistent and the 
resulting HIV-1 reduction is compelling, such an alterna-
tive design may warrant careful consideration.
A change in perspective: additive and relative 
scales in hypothesis testing
One formidable challenge that confronts investigators 
in active-controlled trials of PrEP interventions is the 
heterogeneity of effect sizes in the intent-to-treat (ITT) 
populations across trials, which is probably driven by 
variable adherence levels across populations. This 
variation makes defining NI margins challenging, 
particularly on a multiplicative scale.37 To illustrate, 
consider a scenario with a new agent that is 70% as 
effective as TDF/FTC with an ideal level of adherence. 
due to carryover. Therefore, it would be most useful for 
oral agents for which NI designs are the norm. However, 
methodological research and regulatory scrutiny of this 
design should be conducted to enable assessment of its 
potential for future studies.
Adaptive re-estimation of sample size
During a study, the overall event rate (pooled from both 
arms) can be compared with the assumptions used in 
planning. If the data are examined in a blinded analy-
sis, statistical bias is not a concern, and the sample size 
can be adapted with no statistical adjustments required. 
In contrast, a change in study sample size related to an 
unblinded data analysis (using the observed treatment 
effect or infection rate in one arm) can increase the type 
1 error rate. However, regulatory guidance provides estab-
lished methods for making these adjustments.21,35
The uncertainty about adherence to protocol medica-
tion schedules or the infection rate in a given population 
during a trial make PrEP studies natural candidates for 
ongoing monitoring of each of these factors with clear 
guidelines for adaptations to trial characteristics (cur-
tailment or changes in sample size) in the event of sig-
nificant differences between observed and planned trial 
characteristics.
Addressing an anticipated result of low 
incidence(s)
In a successful NI study, low incidence rates might be 
observed in both arms in the new trial. Whether or not 
the new agent is effective is not obvious because the 
Table 4 Power based on rate difference sample size as-
sumptionsa
aTable shows the probability (power) of establishing non-inferiority, 
based on the upper 1-sided 95% confidence limit for the rate 
difference falling below the specified non-inferiority margin. Value 
of 100 represents > 99.5. Based on simulation of 10,000 trials.
bIncidence per 100 person-years; assumed equal in the 2 groups.






0.5 1.0 1.5 2.0
0.5 500 34 73 95 99
1000 50 93 100 100
1500 63 98 100 100
2000 73 100 100 100
1 500 22 51 78 93
1000 31 72 95 100
1500 40 86 99 100
2000 48 94 100 100
1.5 500 17 39 63 82
1000 23 58 85 97
1500 31 73 96 100
2000 36 83 98 100
2 500 14 32 53 72
1000 20 48 77 94
1500 26 62 90 99
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incidence to the observed risk through a single-arm 
approach using historical controls as described above.
Table 4 shows the effect of rate differences using dif-
ferent NI margins on power. Lower incidence rates in 
the treated groups and numbers of incident infections are 
associated with greater power, which is the opposite of 
inference on a rate-ratio scale. The increased power in the 
lower incidence rate cases derives from an assumption of 
a much higher RR margin. The definition of an acceptable 
NI margin (both scale and size) is a challenging issue. For 
example, should this be a function of the estimated under-
lying incidence of HIV-1 infection in the study population 
or of the incidence of HIV-1 infection anticipated in the 
TDF/FTC arm? To illustrate, excluding a rate difference 
of 0.5 events per 100 person-years requires a very large 
trial, whereas excluding a rate difference of 2.0 events per 
100 person-years may be achievable with a trial of several 
hundred participants (Table 4). A decision could be made 
based on clinical judgment depending on the environment 
surrounding the trial itself, the treatments involved in the 
trial, the uptake of PrEP in the local setting, and reaching 
consensus on the largest clinically acceptable difference.
It is important to re-emphasize that supplementary 
evidence of a high underlying risk of HIV-1 infection in 
the study population is essential for the trial to be inter-
pretable. The data from historical controls previously 
described could be used in projecting what that underly-
ing risk would be.
Conclusion
Important advances have been made in developing 
effective agents to prevent HIV-1 infection, particularly 
in men. While these developments provide tremendous 
benefits for individuals interested in taking PrEP, they 
also impose considerable hurdles for the development 
of new PrEP agents. In the context of low incidence of 
HIV-1 infection and high-adherence rates, traditionally 
designed non-inferiority trials may require unrealistically 
large sample sizes.
Even feasible non-inferiority studies face further chal-
lenges: the difficulty of attributing uniformly low infec-
tion rates to the successful interventions and the difficulty 
of predicting adherence (and any consequent expectations 
of superiority or non-inferiority margins) in the partici-
pants who enter the study.
We propose several innovations to address these 
challenges, each of which may be suitable in a dif-
ferent intervention or trial setting. The interventions 
have the potential to reduce the sample size needed 
to achieve acceptable power. For example, for studies 
exploring a long-acting agent with expectations of bet-
ter adherence than TDF/FTC, a trial could incorporate 
a run-in period during which adherence measures for 
If implemented in a population for whom adherence to 
TDF/FTC yields an ITT effectiveness of 90%, the net 
effectiveness of the new agent is 63% in this population 
– a substantial level of protection. A regulatory agency 
would evaluate the new agent on the strength of this evi-
dence. However, in a population with lower adherence 
levels in which the ITT effectiveness of TDF/FTC is 
50%, the 70% effectiveness relative to TDF/FTC would 
yield a net effectiveness of 35%. Hence, it is difficult 
to specify a single multiplicative margin that would be 
interpreted in the same way for these diverse scenarios. 
This is the major motivation for the discussion men-
tioned previously regarding the pre-specified approach 
to re-estimating the NI margin based on the observed 
adherence level in the trial relative to the assumed 
adherence level that was used for planning purposes. 
However, the additive scale may be worth considering, 
namely the rate difference rather than the ratio of rates. 
Both of these previously mentioned scenarios assume 
the new agent produces an RR reduction that is 70% 
of the reduction produced by TDF/FTC. With a back-
ground HIV infection rate of 3 per 100 person-years for 
a cohort of 10,000 individuals followed for 1 year, 300 
infections would be expected for NPI compared with 
30 infections for active-control treatment and 111 for 
new treatment (Scenario 1). With a background HIV 
infection rate of 8 per 100 person-years for a cohort of 
10,000 individuals followed for 1 year, 800 infections 
would be expected for NPI compared with 80 infections 
for active-control treatment and 296 infections for new 
treatment (Scenario 2). The rate difference in Scenario 
1 is 81 additional infections on the test treatment com-
pared with Scenario 2 with 216 additional infections 
on the test treatment. These considerations can also 
be applied to the justification of NI margins. A mar-
gin of 1.22 requires 1062 events, and a margin of 1.3 
requires 611 events. The difference between these mar-
gins may seem substantial on the relative scale. If the 
background rate of infection is 6 per 100 person-years 
under NPI, this difference in margins could correspond 
to assumed infection rates on control of 2.88% versus 
2.58% (Table 2). An intervention approved under the 
broader margin would allow for an extra 30 infections 
in a cohort of 10,000 people followed for 1 year. This 
information could be helpful in the evaluation of the 
clinical acceptability of different NI margins.
Combining historical controls and the additive scale
An innovative solution would be to consider a process 
that first tests for non-inferiority between the experimental 
agent and the control on the additive scale (i.e. the rate 
difference) and then demonstrates a compelling relative 
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